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Abstract
Background:  Acute hematogenous osteomyelitis (AHO) occurs primarily in children and is
believed to evolve from bacteremia followed by localization of infection to the metaphysis of bones.
Currently, there is no consensus on the route and duration of antimicrobial therapy to treat AHO.
Methods: We conducted a systematic review of a short versus long course of treatment for AHO
due primarily to Staphylococcus aureus in children aged 3 months to 16 years. We searched Medline,
Embase and the Cochrane trials registry for controlled trials. Clinical cure rate at 6 months was
the primary outcome variable, and groups receiving less than 7 days of intravenous therapy were
compared with groups receiving one week or longer of intravenous antimicrobials.
Results: 12 eligible prospective studies, one of which was randomized, were identified. The overall
cure rate at 6 months for the short course of intravenous therapy was 95.2% (95% CI = 90.4, 97.7)
compared to 98.8% (95% CI = 93.6, 99.8) for the longer course of therapy. There was no significant
difference in the duration of oral therapy between the two groups.
Conclusions: Given the potential increased morbidity and cost associated with longer courses of
intravenous therapy, this finding should be confirmed through a randomized controlled equivalence
trial.
Background
Acute hematogenous osteomyelitis (AHO) occurs mainly
in children and is more common in males [1–3]. AHO is
believed to evolve from bacteremia followed by localiza-
tion of infection to the metaphysis of bones. Successful
treatment of AHO is crucial for the prevention of morbid-
ity and functional loss of the affected limb.
Currently, there is no consensus on the route and dura-
tion of antimicrobial therapy to treat AHO. The suggested
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duration of intravenous therapy ranges from 3 days to 4 to
6 weeks. One general pediatric textbook describes 7 days
of parenteral therapy as standard, [4] whereas a pediatric
infectious diseases textbook states that the usual duration
of therapy is 4 to 8 weeks with a change to oral medication
permissible when signs of local inflammation has re-
solved [5]. A standard orthopedic textbook suggests intra-
venous therapy for 5 days followed by oral therapy for 4
to 6 weeks for "typical" cases [6].
Given the paucity of randomized controlled trial evidence
to guide clinicians in the management of children with
AHO, they have typically relied on data presented in ob-
servational studies. The vast majority of these studies have
used a cohort design. Here, a group of children diagnosed
with AHO are identified and treated using antibiotic ther-
apy. The results are usually reported as successful response
rates following a specified period of treatment (e.g., 14
days).
Two studies, each including over 100 children, suggest at
least 3 weeks of intravenous antimicrobial therapy for the
treatment of AHO in children. In these two studies, suc-
cess rates of 82% and 81% were observed in children
treated with intravenous antibiotics for less than 21 days
[7,8]. There is, however, wide variation between studies
regarding failure rates according to treatment duration. A
series of smaller studies quoting 1 to 52 days of parenteral
antimicrobial therapy have reported success rates ranging
from 81% to 100% [9–25]. The aim of our systematic re-
view was to determine whether short courses (less than 1
week) of parenteral antimicrobial therapy show equiva-
lent cure rates compared with longer courses (greater than
1 week) in children with AHO caused primarily by Staphy-
lococcus aureus.
Methods
Search strategy
Medline and EMBASE were searched electronically to help
identify relevant literature from January 1966 to April
2001. The Cochrane Controlled Trials Register, Cochrane
Library was searched from 1981 to July 2000. There were
no restrictions on language or publication status. The lit-
erature was monitored throughout the course of the
project by periodically re-running the search in Medline
and screening newly posted citations. (Please see addi-
tional file 1)
Inclusion criteria
Studies were included if they involved children between 3
months and 16 years of age. The clinical criteria used for
the diagnosis of AHO was: (a) positive culture of Staphylo-
coccus aureus from bone or periosteum; or (b) clinical
signs of osteomyelitis and a concurrent positive blood cul-
ture; or (c) clinical signs and a compatible radiological
study (nuclear scan or radiography). Clinical signs were to
include swelling, warmth, tenderness and decreased abil-
ity to weight bear.
The study design had to meet 3 eligibility criteria: 1) the
study had to be prospective cohort; 2) the intervention
had to identify the antimicrobial and its route (parenteral
or oral) and duration of therapy; and 3) the outcome after
an average of 6 months of follow up had to be stated or
inferable as clinical cure, failure or relapse.
Study selection
Titles and abstracts of each citation were downloaded to a
reference database. Two authors (NLS, AH) independent-
ly screened each citation to determine whether to retain it.
Potentially relevant citations were retrieved and then sub-
jected to a relevance assessment using our eligibility crite-
ria. Open consensus was used to settle differences.
Data abstraction
Once a study met the inclusion criteria, two members of
the research team (NLS; AH) independently abstracted
data using structured data abstraction forms. We captured
information about the report (e.g., language of publica-
tion), design (e.g., cohort), population (e.g., diagnosis),
intervention (e.g., type of antibiotic), and primary out-
come (e.g., response rates). If more than one cohort was
present in a study, data from each cohort was abstracted
separately. Disagreements were resolved by consensus.
Data analysis
Treatment of seven days or less of parenteral therapy was
considered short course. In many institutions the, typical
time required for defervescence, observation, and arrange-
ment of follow-up is about seven days. We thought that
this was a practical point at which to dichotomize for the
purposes of analysis.
When all children are cured, normal theory based confi-
dence intervals for the proportion cured are unavailable,
and when cure rates are close to 100%, normal theory
based confidence intervals may provide poor approxima-
tions. To overcome these problems, Wilson score confi-
dence intervals were computed [26]. Under the
hypothesis of homogeneity of cure rates across cohorts, a
fixed-effect estimate of the overall cure rate is provided by
the total number of cured patients divided by the total
number of patients. The same estimate is provided by an
intercept-only logistic regression model. To test the ho-
mogeneity of cure rates, the residual deviance from the lo-
gistic regression model was compared to a chi-square
distribution with degrees of freedom given by the number
of cohorts minus one.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/16
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Cohorts with different treatments within the same study
were analyzed as separate parallel groups. The difference
between the overall cure rate under short- and long-term
parenteral antimicrobial therapy was assessed using a z-
test. Using the same methods, we performed a sub-group
analysis comparing overall cure rates for beta-lactams and
macrolides. The difference in mean length of oral therapy
for cohorts that had short- and long-term parenteral anti-
microbial therapy was assessed using a t-test. Unlike par-
allel-arm studies, where selective publication of
statistically significant results may produce publication
bias, quite different publication issues may apply to sin-
gle-arm cohort studies. The funnel plot, often used to as-
sess publication bias, is therefore not relevant in this
review.
Results
A flow diagram of the search results is illustrated in Figure
1. Two hundred and eighty-four articles were identified
initially. Of these, 57 articles were considered potentially
relevant. Of these, 34 were small or mixed case series or
had a retrospective study design. Of the remaining 23, 11
Figure 1
Flow diagram outlining the results of literature search and review of studies retrieved.
*Kaplan [38] is not included in the analysis because it is methodologically dissimilar from the other cohortsBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/16
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studies that appeared to be prospective cohorts had either
unusable data, short follow-up or the duration of antimi-
crobial could not be discerned from the data presented
(Table 1). Of the remaining 12 studies, 11 that were of a
prospective design were included in the systematic review
[27–37]. In some cases, only a subset of patients were eli-
gible for inclusion (see notes in Table 2). We excluded one
study of 25 children [38] as it was a different study archi-
tecture. It is inappropriate to combine estimates of effec-
tiveness (i.e., cure rates) from different study types.
The range of duration of parenteral antimicrobial therapy
was 3 to 28 days. Table 2 shows details of the 12 cohort
studies that were used in the analysis. Figure 2 graphically
illustrates the cure rate versus the duration of parenteral
antimicrobial therapy for these cohorts. (Figure 2)
Table 1: Studies which were excluded and the principle reason for exclusion
Study Reason For Exclusion
Unkila-Kallio 1993 Mainly epidemiologic data. Appears to be the cohort from which Peltola 1997 is drawn.
Dones 1994 Small prospective cohort of 4 patients evaluating teicoplanin.
Nelson 1982 Study addressed bactericidal titers. Follow-up did not extend to 6 months although 
reported cure rate was 95% with an average duration of 5 days of intravenous antimicrobi-
als.
Beauvais 1981 Addressed the use of pristinamycin orally. Data was not usable because group could not 
be reliably separated for route and type of antimicrobial.
Fleming 1970 No follow-up data available. Trial focussed on microbiology and side effects of treatment.
Nussinovitch 1997 Data on osteomyelitis cases alone could not be extracted. Maximum follow-up was about 
4 months. Cure appeared to be 95% with mean duration of IV antibiotics of 13.7 days.
Walker 1973 Follow-up was 4 months. Mean duration of intravenous antimicrobials in 14 children was 
4.21 days (range 2–21 days) and cure was 100%.
Bandelon 1988 Group of osteomyelitis and septic arthritis could not be separated with respect to length 
of therapy or etiology.
Kulhanjianv 1989 Only 3 cases of osteomyelitis due to S. aureus.
Aronoff 1986 Of 9 children only 1 child had osteomyelitis alone. No follow-up.
Learmonth 1984 Combined patients with septic arthritis and osteomyelitis. Could not extract data with 
respect to S. aureus alone.
Table 2: Description of studies and the associated cure rates
Author Publication 
year
Sample 
size1
S. aureus 
positive 
culture (%)
Parenteral (IV) 
antimicrobial
Days of IV 
treatment 
Mean 
(range)
Oral
 antimicrobial
Days of oral 
treatment 
Mean 
(range)
Cure rate % 
(CI)
Long Course
Kolyvas2 1980 5 50.03 Cephradine +/- 
Ampicillin
28 (28–28) Cephradine or 
Cloxacillin
18 (14–35) 100 
(67, 100)
Tetzlaff 1978 18 100.0 Methicillin or 
Cefazolin
8 (7–13) Cephalexin or 
Penicillin V
20 (13–42) 94 
(77, 100)
Bryson 1979 18 100.0 Oxacillin or 
Methicillin
7 (5–14) Dicloxacillin N/A (28–56) 100 
(89, 100)
Rodriguez 1977 21 90.5 Clindamycin4 25 (21–28) Clindamycin 42 (42–42) 100 
(91, 100)
Prober 1979 22 100.0 Nafcillin or 
Methicillin
145 (4–28) Dicloxacillin 283 (N/A) 100 
(91, 100)
Short CourseBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/16
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The 7 cohorts that had less than 7 days of intravenous
therapy (n = 146) had a pooled cure rate of 95.2% (95%
confidence interval: 90.4, 97.7) [28–32,35,37]. There was
no significant heterogeneity among their cure rates (chi-
square= 8.2 on 6 df, p= 0.224), indicating that the varia-
tion in cure rates could be attributed to sampling error.
The 5 cohorts who had a duration of intravenous therapy
of 7 days or longer (n = 84) had a pooled cure rate of
98.8% (95% confidence interval; 93.6, 99.8)
[27,31,33,34,36]. There was no significant heterogeneity
among these cure rates (chi-square = 3.1 on 4 df, p =
0.537). Pooling all of the cohorts regardless of duration of
intravenous therapy, there was no significant heterogene-
ity among cure rates (chi-square = 13.7 on 11 df, p =
0.248). The fixed effects model gave a pooled cure rate of
96.5% (95% confidence interval; 93.3, 98.2). There was
no significant difference in the cure rate between the two
groups (z-test p-value 0.838).
Comparing beta-lactams and macrolides, there was no
significant heterogeneity within either group (beta-
lactams; chi square = 7.3 on 7 df, p = 0.394. macrolides;
chi square = 5.2 on 4 df, p= 0.159). The pooled cure rate
for beta-lactams was 95.4% (95% confidence interval;
90.3, 97.9) under a fixed effects model. The pooled cure
rate for macrolides was 98.0% (95% confidence interval;
93.0, 99.4). There was no significant difference in the cure
rate between the two groups (z-test p-value 0.286).
Since the total duration of antimicrobial therapy (i.e.,
parenteral plus oral) can affect the cure rate, we also
looked at the duration of oral therapy. For the cohorts that
had less than 1 week of parenteral therapy, the range of
duration of oral therapy was 15 to 39 days with a mean of
32 days [28–31,35,37]. We could not reliably determine
the mean number of days of oral antimicrobials from one
study [32]. For the cohorts that were given a longer dura-
tion of intravenous therapy, the range of duration of oral
therapy was 18 to 56 days with a mean of 33 days
[27,31,33,34,36]. There was no significant difference in
the duration of oral therapy between the two groups (t-
test p-value 0.888).
Among the group who had short-term antimicrobials, the
percentage of children that had surgery ranged from 30%
to 'routine' or probably over 90% [28–31,35,37]. Two au-
thors did not state the percentage of children who re-
quired surgery [29,32]. Among the long-term group, the
range is from 50 to 90% [27,31,33,34,36]. It was not stat-
ed explicitly in most cases whether these procedures were
for diagnostic or therapeutic purposes.
The number of children with septic arthritis in the short
course group ranged from 0 to 40% [29,31,35,37]. In
Kolyvas2 1980 5 50.03 3 (N/A) Cephradine or 
Cloxacillin
423 (39–60)3 100 
(67, 100)
Refass6 1989 6 98.9 Cloxacillin N/A (5–6) Flucloxacillin N/A (7–200)3 100 
(72, 100)
Freij 1987 8 100.0 Imipenem + 
Cilastatin
5.5 (4–9) Cefaclor or 
Dicloxacillin or 
Cephalexin or 
Bacampicillin or 
Penicillin V
15 (13–19) 88 
(55, 100)
Feigin7 1975 11 72.7 Clindamycin 6 (3–13) Clindamycin 425 (N/A) 91 
(65, 100)
Geddes8 1977 18 65.03 Clindamycin 63 (N/A) Clindamycin 903(N/A) 94 
(77, 100)
Cole9 1982 48 94.5 Cloxacillin or 
Cephalothin
3 (2–5) Cloxacillin or 
Cephalexin
39 (37–40) 92 
(81, 97)
Peltola 1997 50 100.0 Cephradine or 
Cephalothin or 
Clindamycin
4 (4–6) Cefadroxil or 
Clindamycin
19 (17–19) 100 
(96, 100)
1 Includes cases that were due to Staphylococcus aureus and those who were culture negative 2 Included only the cases that had osteomyelitis alone 
or had contiguous arthritis and osteomyelitis. 3 Estimated value. 4 Clindamycin is the only macrolide studied – all other antimicrobials mentioned 
are beta-lactams. 5 Median reported. 6 Only the 6 patients who clearly met the diagnostic criteria were included. 7 Data abstracted from the 11 
cases of osteomyelitis (8 of whom had S. aureus). 8 Only data for the 18 children with acute osteomyelitis from the study were included. Some of 
these may only have received oral medication. 9 Data from the 48 patients for whom there was follow-up of greater than 6 months.
Table 2: Description of studies and the associated cure rates (Continued)BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/16
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three studies the exact number could be deduced,
[28,30,32] whereas in the 5 cohorts who were given great-
er than 7 days of therapy, 0% to 20% of children had con-
comitant septic arthritis [27,31,33,34,36].
Discussion
The epidemiology of childhood AHO has changed since
routine childhood immunization against Haemophilus in-
fluenzae type b was introduced in the early 1990s [39].
Currently, the most common causative organism of child-
hood AHO is Staphylococcus aureus. For AHO therapy to be
successful, levels of antimicrobial agents must be main-
tained sufficiently high over time to eliminate the bacteria
from the site of infection. Pharmacologic evidence for ad-
equate concentrations of oral antimicrobial agents in af-
fected tissues supports the use of oral agents within a
management scheme of 'step-down therapy.' [34,36] The
benefits of shorter courses of parenteral antimicrobial
Figure 2
Cure rate versus the duration of parenteral antimicrobial therapy Long-term parenteral antimicrobials is defined as
greater than or equal to 7 days. Short-term parenteral antimicrobials is defined as less than 7 daysBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/16
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therapy before switching to oral therapy include decreased
costs and morbidity. There still exists, however, a dilem-
ma with respect to the optimal duration of parenteral
therapy.
Our systematic review of cohort studies using a minimum
follow up of 6 months found a pooled cure rate of 95.2%
(95% CI = 90.4 – 97.7) with 7 days or less of parenteral
therapy. Other cohorts that had short follow-up (there-
fore not included in our review) reported treating children
with less than 7 days of parenteral antimicrobial reported
cure rates of greater than 90%; [40,41]. In one other co-
hort (not suitable for inclusion in our analysis due to un-
extractable data, heterogeneous group and a follow up
period of 4 months), a 95% cure rate was observed with
14 days of parenteral antimicrobial therapy [42]. Many
other prospective studies could not be included in the sys-
tematic review for a variety of reasons: lack of standard-
ized definitions, lack of retrievable treatment information
or short follow-up periods [2,19,40–49].
The small sample size used (mean of 24 patients; range 5
to 50 patients) is of concern although we gained statistical
strength by pooling across studies. Thus, individual stud-
ies have wide confidence intervals, which are narrowed
using the systematic review approach, providing a more
precise estimate of the "true" cure rates (Figure 1). The
range of duration of oral antimicrobial agents was also
wide, implying that there may have been other clinical
factors that were implicit in the decision of total length of
therapy. Other clinical parameters, such as the extent of
bone involvement, suspicion of septic arthritis and the
course of the illness before treatment, may also have influ-
enced treatment duration, but were not reported. Al-
though the studies were prospective cohorts with respect
to length of therapy they may be inherently biased in their
selection criteria.
We did not assess the quality of reports of the included
studies. Quality assessment is an important part of a sys-
tematic review, particularly if a validated approach is used
[50]. We are unaware of any published assessment meas-
ure for cohort studies and elected to forgo the pitfalls of
developing one ourselves [51].
Clinical heterogeneity in the data from older studies can
be partly attributed to the multiple pathogens that were
responsible for the clinical syndrome. Only one study was
published after routine childhood immunization for Hae-
mophilus influenzae type b was introduced in the early 90's
[35]. We included children who had had disease due to
Staphylococcus aureus as well as those who were culture
negative because in many cases this reflects the reality of
clinical practice. Studies that deal only with staphylococ-
cal disease or that were published after 1990 from areas
where there is universal immunization against Haemophil-
us influenzae type b are most likely to best represent the
child who currently presents with AHO due to methicillin
sensitive Staphylococcus aureus (MSSA).
Our review had several limitations. We narrowed our fo-
cus to cohort studies. Results from randomized controlled
trials may provide more valid results and we are aware of
the existence of at least one such study [38]. The cure rate
of 91.6% in children who received short course parenteral
therapy however supports the findings of this systematic
review. This report however only included 12 children in
that group. Combining this study with the cohort studies
might introduce bias into the estimates of cure rates.
Our results indicate that cure rates are similar regardless of
whether children with AHO are treated for a shorter or
longer time period. There are several potential practical
advantages of the shorter course of therapy; shorter hospi-
tal stay; decreased morbidity from intravenous lines and
more cost effective. We believe that the results from this
systematic review warrant serious consideration be given
to conducting a randomized controlled trial. Such a study
could be developed to demonstrate equivalence between
two durations of antibiotic therapy: a shorter course (i.e.,
3–5 days) compared to a more "standard" course of 14 to
21 days. This would only be relevant if cure rates were not
equivalent. The results from such a study could be used to
better inform clinicians as to the management of children
with AHO in the future.
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